Common-Size Income Statement
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Analysis of Long-term (Investment) Activity Ratios
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Current Ratio since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Vertex Pharmaceuticals Inc., common-size consolidated income statement
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
| Income statement item | Description | The company |
|---|---|---|
| Income from operations | The net result for the period of deducting operating expenses from operating revenues. | Vertex Pharmaceuticals Inc. income from operations as a percentage of revenues increased from 2021 to 2022 but then slightly decreased from 2022 to 2023 not reaching 2021 level. |
| Income before provision for income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Vertex Pharmaceuticals Inc. income before provision for income taxes as a percentage of revenues increased from 2021 to 2022 but then slightly decreased from 2022 to 2023. |
| Net income | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Vertex Pharmaceuticals Inc. net income as a percentage of revenues increased from 2021 to 2022 but then slightly decreased from 2022 to 2023. |